| Outcome Measures: |
Primary: Change From Baseline in Fasting Plasma Glucose (FPG) at Week 12., Change from baseline in fasting plasma glucose in response to three different doses of Mitoglitazone as compared to pioglitazone following once-daily dosing for 84 consecutive days (12 weeks) in patients with Type 2 diabetes., Baseline, Week 12 | Secondary: Change From Baseline in HbA1c, Change from baseline in plasma glucose measured by hemoglobin A1c in response to three different doses of Mitoglitazone and pioglitazone as compared to placebo following once-daily dosing for 84 consecutive days (12 weeks) in patients with Type 2 diabetes., 12 weeks|Percent Change From Baseline to Week 12 Endpoint in HMW Adiponectin, Percent change from baseline to week 12 endpoint in high molecular weight adiponectin, 12 weeks|Change From Baseline to Week 12 Endpoint in Hematocrit, Change from baseline to week 12 endpoint in hematocrit as an indication of fluid retention, 12 weeks|Change From Baseline in Hemoglobin, Change from baseline at week 12 endpoint in hemoglobin concentration, 12 weeks|Change From Baseline in RBC, Change from baseline at week 12 endpoint in red blood cell concentration, 12 week|Change in Body Weight From Baseline to Week 12 Endpoint, Effects of 3 different doses of Mitoglitazone and pioglitazone as compared to placebo on body weight following once-daily dosing for 12, 12 weeks|Change From Baseline in Waist Circumference at Week 12 Endpoint, Effects of 3 different doses of Mitoglitazone and pioglitazone as compared to placebo on waist circumference following once-daily dosing for 12 weeks, 12 weeks|Presence of Edema Post Baseline During 12 Weeks Active Treatment, Effects of 3 different doses of Mitoglitazone and pioglitazone as compared to placebo on presence of edema following once-daily dosing for 12 weeks, 12 weeks|Changes in HDL Particle Size Subfractions From Baseline to Week 12, Effects of 3 different doses of Mitoglitazone and pioglitazone as compared to placebo on HDL particle size profile as characterized by changes in NMR analysis of subfractions following once-daily dosing for 12 weeks, 12 weeks|Changes in LDL Particle Size Subfractions From Baseline to Week 12, Effects of 3 different doses of Mitoglitazone and pioglitazone as compared to placebo on LDL particle size profile as characterized by changes in NMR analysis of subfractions following once-daily dosing for 12 weeks, 12 week
|
| Locations: |
Huntsville, Alabama, United States|Muscle Shoals, Alabama, United States|Chino, California, United States|Los Angeles, California, United States|Spring Valley, California, United States|Walnut Creek, California, United States|Miami, Florida, United States|New Port Richley, Florida, United States|Palm Harbor, Florida, United States|Pembroke Pines, Florida, United States|Marietta, Georgia, United States|Chicago, Illinois, United States|Indianapolis, Indiana, United States|Grand Rapids, Michigan, United States|Cincinnati, Ohio, United States|Kettering, Ohio, United States|Tiffin, Ohio, United States|Oklahoma City, Oklahoma, United States|Eugene, Oregon, United States|Portland, Oregon, United States|Greer, South Carolina, United States|Corpus Christi, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States
|
